Biocon is an integrated biotechnology company in India that encompasses all critical stages of drug development – drug discovery, development,…
Strong brands, improved strategy execution, and enhanced distribution efforts get the company a leg-up on the market
L&T’s new 5-year (FY 17-21) plan envisages 12-15% annual sales growth, 120bps margin improvement and reducing net working capital intensity…
Aurobindo started FY17 in the same way as it spent most of FY16 — announcing two more approvals on day…
The RBI cut its key repo rate by 25bps and maintained an accommodative bias as expected (despite signaling upside risks…
IndiGo Airlines issued its inaugural set of results following the Nov 2015 IPO. During FY3Q16 (December), operating Revenue improved 11%…
New project announcements fell sharply in both government and private sectors, with the absolute figures being the lowest since Modi…
Company is the best play on India’s infrastructure development and economic growth
‘Buy’ Lupin with a target price of R2,550 a share. We value Lupin at 27x March 2017e forward earnings, at…
After a light FY15, ARBN has received 15 approvals in FY16 YTD. This is a mix of plain-vanilla and limited…
Exit from consumer electricals, loss-making international biz could trigger re-rating
The boardroom challenge to CEO & primary shareholder (~11.8%) Rana Kapoor from the family of a copromoter (~10.3%) has got…
Well-placed to deliver growth once US approvals pick up
Growth visibility is reducing at the margin
Buy Bharat Petroleum Corp (BPCL) with target price of R887. We use use a 7x target EV/ebitda multiple on an…
Stock strategies should now focus on asset quality, loan growth
We attribute three reasons, global orders, valuations and capex cycle, for upgrading L&T to ?buy?. With the domestic economy stuttering,…
There is the silver lining: SBI has surplus liquidity, monsoons have been good.
